Breaking News

The WHO Recommends COVID-19 Monoclonal Antibody Treatment

January 14, 2022 • 5:56 am CST
(Precision Vaccinations)

The World Health Organization (WHO) today announced it has conditionally recommended using the monoclonal antibody sotrovimab (Xevudy) for treating mild or moderate COVID-19 in patients at high risk of hospitalization.

The WHO recommendation for sotrovimab includes older, immunocompromised patients who have underlying conditions like diabetes, hypertension, obesity, and those who are unvaccinated.

Today's recommendation is included in the eighth update of WHO's living guidelines on therapeutics and COVID-19, based on evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19.

In addition, the WHO is in discussions with manufacturers to secure global supply capacity and equitable and sustainable access to the newly recommended therapeutics. Sotrovimab has been invited for WHO Prequalification, which assesses the quality, efficacy, and safety of priority health products to increase access in lower-income countries.

GSK and Vir Biotechnology's Sotrovimab (Xevudy) is a pan-sarbecovirus anti-SARS-CoV-2 monoclonal antibody selected based on its potential to neutralize the betacoronavirus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the essential sites of infection).

As of January 14, 2022, the U.S. NIH DataPortal indicates sotrovimab protects against the Omicron virus variant.